Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
68 NC counties are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Closings
118 closings/delays reported, including Durham and Wake public schools.
Just In
Helene update: Category 4 storm continues gaining strength with 140 mph winds as it nears Florida. Tornado watches issued for southern NC counties
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
191.90
+0.64 (+0.33%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
67
68
Next >
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
April 26, 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
April 26, 2024
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
Via
Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
April 26, 2024
Skyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira.
Via
Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
April 26, 2024
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AbbVie's Options Frenzy: What You Need to Know
April 23, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
April 17, 2024
Via
Benzinga
AbbVie's Options Frenzy: What You Need to Know
April 15, 2024
Via
Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
April 25, 2024
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
Via
InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
April 23, 2024
It's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay.
Via
InvestorPlace
Buying the Dip in These 3 Undervalued Dividend Stocks
April 22, 2024
All three of these stocks look intriguing.
Via
The Motley Fool
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
April 22, 2024
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more.
Via
InvestorPlace
Is AbbVie a Millionaire Maker?
April 14, 2024
Everything is going according to plan, and more growth is on the way.
Via
The Motley Fool
Smart Money Is Betting Big In ABBV Options
April 12, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
April 20, 2024
The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.
Via
The Motley Fool
Topics
ETFs
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
April 19, 2024
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
Via
InvestorPlace
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
April 19, 2024
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."
Via
Investor's Business Daily
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
April 18, 2024
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.
Via
Benzinga
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
April 17, 2024
Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision issues, difficulty breathing, and weakness. Ensure authenticity before...
Via
Benzinga
Exposures
Product Safety
Powell And The Great Indecision
April 16, 2024
In today’s presser, Powell basically said what he typically says. Higher for longer but maybe not as risks remain to the economy while inflation is too sticky.
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
April 16, 2024
With an already tense situation becoming even more troubling, now’s the time to consider blue-chip dividend stocks to buy.
Via
InvestorPlace
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via
Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
April 15, 2024
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Via
Investor's Business Daily
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
April 12, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
What's Going On AbbVie Stock On Friday?
April 12, 2024
AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as Qulipta...
Via
Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
April 12, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
April 11, 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
Via
InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
April 10, 2024
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
67
68
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.